Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Contact
c/- Perks, 81 Flinders Street
Level 8
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
stocks
Wide moat airport share steps up its investments
Profits flatten as airport ramps up redevelopment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.70 | 9.20 | 0.10% |
| CAC 40 | 8,448.34 | 36.09 | -0.43% |
| DAX 40 | 26,079.70 | 56.86 | -0.22% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,801.47 | 15.09 | -0.14% |
| HKSE | 25,517.33 | 492.13 | -1.89% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 65,528.09 | 488.27 | -0.74% |
| NZX 50 Index | 13,881.88 | 90.78 | -0.65% |
| S&P 500 | 7,674.37 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,103.10 | 9.90 | 0.11% |
| SSE Composite Index | 3,882.01 | 23.19 | -0.59% |